Prosecution Insights
Last updated: November 04, 2026

Gto Pharma LLC

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Gto Pharma LLC has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The portfolio's current activity is handled by 1 distinct examiner and 1 distinct art unit. KWON, YONG SOK is the busiest examiner, with 1 pending action currently under review.

This distribution indicates a highly focused prosecution effort within a specific niche of Biotechnology & Pharmaceuticals. Since only 1 distinct examiner is involved, the company's immediate patent prospects depend on the feedback from KWON, YONG SOK. Practitioners should analyze the examiner's past decisions to better understand the potential challenges for the 1 pending office action.

The singular focus on 1 distinct art unit and one examiner provides a clear but narrow path for the company's current intellectual property strategy. Success in this 1 action will be a critical step for the company's overall patent goals. Practitioners should monitor the specific procedural history of this matter to ensure all examiner requirements are met efficiently and to predict the future trajectory of the portfolio.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
0
Due this month
1
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
KWON, YONG SOK 1 23.8% +42.8%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18668135 COMPOUNDS AND FORMS OF TREATMENT FOR FEMALE SEXUAL DISORDERS KWON, YONG SOK 50d

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18668135 COMPOUNDS AND FORMS OF TREATMENT FOR FEMALE SEXUAL DISORDERS KWON, YONG SOK 50d

Top Art Units

Art UnitApps
1613 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18668135 COMPOUNDS AND FORMS OF TREATMENT FOR FEMALE SEXUAL DISORDERS KWON, YONG SOK 1613 §101§102§103§112Other Non-Final OA 50d Pending May 18, 2024

Managing Gto Pharma LLC's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Gto Pharma LLC have?

Gto Pharma LLC has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Gto Pharma LLC applications?

Yong Sok Kwon has the most, with 1 of Gto Pharma LLC's pending office actions.

What technology area are Gto Pharma LLC's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month